Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2593–2616 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions: Camoteskimab, Placebo; Drug
Lead sponsor: Apollo Therapeutics Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 30
States / cities: Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more

Conditions: Surgery, Non Diabetic Hyperglycemia
Interventions: glucose, insulin, and potassium (GIK), Crystalloid Infusion; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Osteoarthritis
Interventions: Active Device (Torino II), Sham Device (Torino II); Device
Lead sponsor: Center for Joint Surgery and Sports Medicine, Maryland; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Hagerstown, Maryland

Conditions: Type 2 Diabetes Mellitus
Interventions: HIP2B, Placebo; Drug
Lead sponsor: CureDM; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Rib Fractures
Interventions: ON-Q bupivicaine administration, IV opioid administration; Device · Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: Gut Health
Interventions: Butyrate Formulation, Butyrate + Polyphenol Formulation, Placebo; Dietary Supplement
Lead sponsor: Supplement Formulators, Inc.; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Asthma
Interventions: Exhaled nitric oxide (eNO); Device
Lead sponsor: Apieron; Industry
Eligibility: 5 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: Shreveport, Louisiana • Lake Oswego, Oregon

Conditions: HIV Infections, Alcoholism
Interventions: Brief alcohol intervention based on Project Treat, Standard care; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: Female only
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infant, Newborn
Interventions: Darbepoetin Alfa Injection, erythropoietin alfa injection, sham injection; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 1 Hour to 49 Hours
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Denver, Colorado • Ogden, Utah • Salt Lake City, Utah

Conditions: Clostridioides Difficile Infection
Interventions: Ridinilazole, Vancomycin; Drug
Lead sponsor: Summit Therapeutics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 18
States / cities: Los Angeles, California • Orange, California • Miami, Florida + 11 more

Conditions: SARS-CoV 2
Interventions: Tocilizumab, Placebos; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: Boston, Massachusetts • Newton, Massachusetts

Conditions: Nocturia, Daytime Sleepiness
Interventions: Armodafinil, Placebo; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epilepsy
Interventions: Vitamin E; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 1 Year to 18 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Asthma
Interventions: Vilanterol, Salmeterol Inhalation Powder, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder Diskus; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 11
States / cities: Huntington Beach, California • Orlando, Florida • Tallahassee, Florida + 8 more

Conditions: Psoriatic Arthritis
Interventions: Tofacitinib, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 43
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 33 more

Conditions: Asthma, Allergic
Interventions: REGN3500, Dupilumab, Placebo, Fluticasone propionate; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cypress, California

Conditions: COVID-19, ARDS
Interventions: SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV; Biological · Other
Lead sponsor: Edesa Biotech Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Fresno, California • Fullerton, California • Coral Gables, Florida + 4 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: Glutamine, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 1,433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 15
States / cities: Birmingham, Alabama • Palo Alto, California • San Diego, California + 12 more

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Opioid Use, Pain, Postoperative
Interventions: Bupivacaine, Dexamethasone, Saline; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections, AIDS-Associated Nephropathy
Interventions: Prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Torrance, California + 4 more

Conditions: Alzheimer's Disease
Interventions: T3D-959, Placebo Comparator; Drug · Other
Lead sponsor: T3D Therapeutics, Inc.; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Prevention and Treatment of Common Hyperglycemia in Surgery Pilot

Use of Pulsed Electromagnetic Fields for Postoperative Knee Pain

Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin

Pain Relief for Ventilated Patients With Multiple Rib Fractures Using the ON-Q Pain Relief System

Naltrexone/Bupropion Cardiovascular Outcomes Study

Effectiveness of a Butyrate Formulation and Butyrate + Polyphenol Formulation on Gut Health, Permeability and Associated Symptoms

Measuring Exhaled Nitric Oxide (eNO) Using the Apieron INSIGHT System and the Aerocrine NIOX System

Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women

Darbepoetin Administration to Preterm Infants

Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects

Efficacy of Tocilizumab on Patients With COVID-19

Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia

Double-Blind, Placebo-Controlled Trial of Vitamin E as Add-on Therapy for Children With Epilepsy

Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors

Study of REGN3500 and Dupilumab in Patients With Asthma

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19

Glutamine Supplementation to Prevent Death or Infection in Extremely Premature Infants

A Study With Imlifidase in Anti-GBM Disease

Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy of Prednisone Therapy in HIV-Associated Nephropathy (HIVAN)

A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects